Abstract
Phosphoribosyl pyrophosphate synthetase 1 (PRPS1) is a key enzyme in de novo nucleotide synthesis and nucleotide salvage synthesis pathways that are critical for purine and pyrimidine biosynthesis. Abnormally high expression of PRPS1 can cause many diseases, including hearing loss, hypotonia, and ataxia, in addition to being associated with neuroblastoma. However, the role of PRPS1 in neuroblastoma is still unclear. In this study, we found that PRPS1 was commonly expressed in neuroblastoma cells and was closely related to poor prognosis for cancer. Furthermore, down-regulation of PRPS1 inhibited neuroblastoma cell proliferation and tumor growth in vitro and in vivo via disturbing DNA synthesis. This study provides new insights into the treatment of neuroblastoma patients and new targets for drug development.
Highlights
Neuroblastoma is one of the most common types of solid tumor and exhibits high malignancy rates in children [1,2,3,4]
To investigate whether pyrophosphate synthetase 1 (PRPS1) is associated with neuroblastoma patient prognosis, a Kaplan–Meier analysis based on the R2 database was first conducted
We determined that PRPS1 expression was a potential prognostic marker in neuroblastoma patients
Summary
Neuroblastoma is one of the most common types of solid tumor and exhibits high malignancy rates in children [1,2,3,4]. Neuroblastoma has a poor prognosis, metastasizes, recurs frequently, and is very heterogeneous [6,7,8]. Neuroblastoma can be divided into three types based on the degree of differentiation: undifferentiated, poorly differentiated, and differentiated. A small number of neuroblastoma cases can transform into benign tumors spontaneously with little or no systemic treatment. Neuroblastoma is self-regressing and differentiates in vitro, rendering it a good tumor model to understand the mechanisms of cancer cell proliferation and differentiation and identify new strategies for clinical treatment [6,9,10,11]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
